These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
382 related articles for article (PubMed ID: 24255129)
1. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129 [TBL] [Abstract][Full Text] [Related]
2. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M; Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816 [TBL] [Abstract][Full Text] [Related]
3. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195 [TBL] [Abstract][Full Text] [Related]
4. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR; J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292 [TBL] [Abstract][Full Text] [Related]
5. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620 [TBL] [Abstract][Full Text] [Related]
6. Effects of Serelaxin in Patients with Acute Heart Failure. Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C; N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919 [TBL] [Abstract][Full Text] [Related]
7. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454 [TBL] [Abstract][Full Text] [Related]
8. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU. Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559 [TBL] [Abstract][Full Text] [Related]
10. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697 [TBL] [Abstract][Full Text] [Related]
11. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial. Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893 [TBL] [Abstract][Full Text] [Related]
13. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP). Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767 [TBL] [Abstract][Full Text] [Related]
14. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178 [TBL] [Abstract][Full Text] [Related]
15. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463 [TBL] [Abstract][Full Text] [Related]
16. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour. Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360 [TBL] [Abstract][Full Text] [Related]
17. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Erdmann E; Semigran MJ; Nieminen MS; Gheorghiade M; Agrawal R; Mitrovic V; Mebazaa A Eur Heart J; 2013 Jan; 34(1):57-67. PubMed ID: 22778174 [TBL] [Abstract][Full Text] [Related]
18. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514 [TBL] [Abstract][Full Text] [Related]
19. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) JAMA; 2002 Mar; 287(12):1531-40. PubMed ID: 11911755 [TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Marcus LS; Hart D; Packer M; Yushak M; Medina N; Danziger RS; Heitjan DF; Katz SD Circulation; 1996 Dec; 94(12):3184-9. PubMed ID: 8989127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]